Biogen (BIIB)

Q: What's priced into Biogen (BIIB) stock?

The market appears to have a neutral valuation stance on BIIB, with expectations slightly below peers. There is a low fragility tier, indicating that the current pricing reflects justified fundamentals without significant risk of sharp declines.

Q: What does the Biogen (BIIB) outlook hinge on?

The thesis hinges on the ability of management to maintain guidance and deliver on pipeline advancements. Additionally, performance of sector bellwethers will be crucial in shaping market sentiment around BIIB.

NASDAQHealth CareDrug Manufacturers - GeneralSnapshot 2026-10-15

$232.65-1.15%

Close 2026-10-16 · 1-day change

Read the published Living FV report summary

Investment OutlookAs of Oct 15, 2026

What could strengthen or challenge Biogen’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

-0.3%

+10% or more+5%0%−5%−10% or less

16.55 → 16.50 EPS · FY ending Dec 31, 2027 · 20 analysts

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

Change in the same fiscal period’s mean EPS estimate from Sep 15, 2026 to Oct 15, 2026: (new ÷ prior − 1). Contributor count changed from 19 to 20; this is not the number of analysts revising. Source: FMP consensus snapshots. The ±10% axis is a display range.

Living FV™

Living Fair Value by QuarterlyIQ

A valuation that evolves as the business changes.

A published Living FV snapshot is not available yet. The valuation workflow remains discoverable; a market target cannot supply the missing evidence.

View Living FV report and workflow

What the Thesis Depends On

4 key conditions need to be met for the investment thesis to play out.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Maintain free cash flow yield near 8%	Profit margins remain stable with steady cash flow.	Intact	FCF yield falls below 8%	Free cash flow yield: 7.71% As of 2026-10-15; trailing twelve months. The target timing and basis require a separate assessment. Market data as of Oct 15, 20267.71 percent · calculatedLast status assessment Oct 15, 2026 Measurement source consolidated · TTM valuation Period ending Oct 15, 2026 Source: mart.stock_valuation_daily. Reference: BIIB:2026-10-15. Source status: canonical calculation. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Achieve EPS between $14.25 and $15.25 in 2026 and grow to $16.63 in 2027	A primary condition in Biogen's published investment case. The stated target is EPS 2026 between $14.25 and $15.25; EPS 2027 >= $16.63.	Intact	EPS falls below $14.25 in FY26 or below $16.63 in FY27	Diluted EPS: $0.66 per share FY2026-Q2; GAAP. Published target: EPS 2026 between $14.25 and $15.25; EPS 2027 >= $16.63. Target period is not explicitly aligned with this observation. Source published Jul 29, 20260.66 USD/share · source valueSource reportLast status assessment Oct 15, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: d45a4f89-9277-4003-b8bb-d89bc616bce7. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Successful integration and pipeline expansion from acquisitions	A supporting condition in Biogen's published investment case. The stated target is Pipeline and business development progress supporting growth.	Improving	Significant setbacks or pipeline reductions from acquisitions	Qualitative: Pipeline expansion confirmed (Apellis acquired, Zorevunersen data, new Alzheimer's launch) Biogen completed Apellis acquisition, launched new Alzheimer's injection, and presented positive Zorevunersen data, reinforcing pipeline growth. Context reviewed through Oct 15, 2026Last status assessment Oct 15, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Manage mid-single digit revenue decline in 2026	Biogen manages a mid-single digit revenue decline in 2026.	Intact	revenue decline exceeds 5% YoY in FY26	Revenue growth: 3.42% FY2026-Q2; GAAP. Published target: revenue decline <= 5% YoY. Target period is not explicitly aligned with this observation. Source published Jul 29, 20263.420903 percent · calculatedSource reportLast status assessment Oct 15, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: d45a4f89-9277-4003-b8bb-d89bc616bce7. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$16.50

$16.46 → $16.50 · observed estimates

FY2027 revenue$10.67B

$10.33B → $10.67B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$16.46	$10,329,510,180	29 / 28
2026-07-25	$16.39	$10,317,219,830	28 / 27
2026-07-26	$16.39	$10,317,219,830	28 / 27
2026-07-27	$16.42	$10,318,175,650	28 / 27
2026-07-28	$16.42	$10,318,175,650	28 / 27
2026-07-29	$16.48	$10,321,904,360	29 / 28
2026-07-30	$16.48	$10,321,904,360	29 / 28
2026-07-31	$16.54	$10,545,444,630	19 / 25
2026-08-01	$16.48	$10,321,904,360	29 / 28
2026-08-02	$16.57	$10,620,066,450	31 / 30
2026-08-03	$16.57	$10,620,066,450	31 / 30
2026-08-04	$16.57	$10,620,066,450	31 / 30
2026-08-05	$16.59	$10,624,903,010	32 / 31
2026-08-06	$16.59	$10,624,903,010	32 / 31
2026-08-07	$16.59	$10,628,614,883	21 / 26
2026-08-08	$16.59	$10,624,910,590	32 / 31
2026-08-09	$16.59	$10,624,910,590	32 / 31
2026-08-10	$16.59	$10,624,910,590	32 / 31
2026-08-11	$16.59	$10,628,614,883	21 / 26
2026-08-12	$16.60	$10,635,425,480	32 / 31
2026-08-13	$16.60	$10,635,425,480	32 / 31
2026-08-14	$16.59	$10,628,614,883	21 / 26
2026-08-15	$16.59	$10,628,614,883	21 / 26
2026-08-16	$16.59	$10,628,614,883	21 / 26
2026-08-17	$16.59	$10,628,614,883	21 / 26
2026-08-18	$16.59	$10,628,614,883	21 / 26
2026-08-19	$16.59	$10,628,614,883	20 / 26
2026-08-20	$16.54	$10,661,768,964	20 / 26
2026-08-21	$16.54	$10,661,768,964	20 / 26
2026-08-22	$16.54	$10,661,768,964	20 / 26
2026-08-23	$16.54	$10,661,768,964	20 / 26
2026-08-24	$16.54	$10,661,768,964	20 / 26
2026-08-25	$16.54	$10,661,768,964	20 / 26
2026-08-26	$16.54	$10,661,768,964	19 / 26
2026-08-27	$16.54	$10,661,768,964	19 / 26
2026-08-28	$16.54	$10,661,768,964	19 / 26
2026-08-29	$16.54	$10,661,768,964	19 / 26
2026-08-30	$16.54	$10,661,768,964	19 / 26
2026-08-31	$16.54	$10,661,768,964	19 / 26
2026-09-01	$16.54	$10,661,768,964	19 / 26
2026-09-02	$16.54	$10,661,768,964	19 / 26
2026-09-03	$16.55	$10,668,863,299	19 / 26
2026-09-04	$16.55	$10,668,863,299	19 / 26
2026-09-05	$16.55	$10,668,863,299	19 / 26
2026-09-06	$16.55	$10,668,863,299	19 / 26
2026-09-07	$16.55	$10,668,863,299	19 / 26
2026-09-08	$16.55	$10,668,863,299	19 / 26
2026-09-09	$16.55	$10,668,863,299	19 / 26
2026-09-10	$16.55	$10,668,863,299	19 / 26
2026-09-11	$16.55	$10,668,937,955	19 / 26
2026-09-12	$16.55	$10,668,937,955	19 / 26
2026-09-13	$16.55	$10,668,937,955	19 / 26
2026-09-14	$16.55	$10,668,937,955	19 / 26
2026-09-15	$16.55	$10,668,937,955	19 / 26
2026-09-16	$16.55	$10,668,937,955	19 / 26
2026-09-17	$16.55	$10,668,937,955	19 / 26
2026-09-18	$16.55	$10,668,937,955	19 / 26
2026-09-19	$16.55	$10,668,937,955	19 / 26
2026-09-20	$16.55	$10,668,937,955	20 / 27
2026-09-21	$16.55	$10,668,937,955	20 / 27
2026-09-22	$16.55	$10,668,937,955	20 / 27
2026-09-23	$16.55	$10,668,937,955	20 / 27
2026-09-24	$16.55	$10,668,937,955	20 / 27
2026-09-25	$16.55	$10,668,937,955	20 / 27
2026-09-26	$16.55	$10,668,937,955	20 / 27
2026-09-27	$16.55	$10,668,937,955	20 / 27
2026-09-28	$16.55	$10,668,937,955	20 / 27
2026-09-29	$16.55	$10,668,937,955	20 / 27
2026-09-30	$16.55	$10,668,937,955	20 / 27
2026-10-01	$16.55	$10,668,937,955	20 / 27
2026-10-02	$16.55	$10,668,937,955	20 / 27
2026-10-03	$16.55	$10,668,937,955	20 / 27
2026-10-04	$16.55	$10,668,937,955	20 / 27
2026-10-05	$16.55	$10,668,937,955	20 / 27
2026-10-06	$16.55	$10,668,931,504	20 / 27
2026-10-07	$16.55	$10,669,608,923	20 / 27
2026-10-08	$16.55	$10,669,608,923	20 / 27
2026-10-09	$16.53	$10,666,937,955	20 / 27
2026-10-10	$16.53	$10,666,937,955	20 / 27
2026-10-11	$16.55	$10,674,393,750	20 / 27
2026-10-12	$16.55	$10,674,393,750	20 / 27
2026-10-13	$16.57	$10,674,942,137	20 / 27
2026-10-14	$16.50	$10,674,432,607	20 / 27
2026-10-15	$16.50	$10,674,432,607	20 / 27

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold	Sell*
2026-05-01	21	16	1
2026-06-01	21	15	1
2026-07-01	23	14	1
2026-08-01	24	12	1
2026-09-01	23	12	1
2026-10-01	24	12	1

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 24 Buy / Strong Buy · 12 Hold · 1 Sell / Strong Sell

1 upgrades0 downgrades2 maintains

Recent actions · Sep 16–Oct 15 · 3 recorded

Price-target changes

30 days

○ Previous · ● Latest · common dollar scale

BMO CapitalOct 12

$220.00New observation · no comparable prior

UBSOct 9 · prior Jul 30

$240.00 → $270.00+12.5%

RBC CapitalOct 8 · prior Aug 25

$260.00 → $256.00-1.5%

$0$148.50$297.00

1 raises · 1 cuts · 0 unchanged · 1 without a comparable prior

How this is measured

Sep 16, 2026–Oct 15, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Maintain free cash flow yield near 8%Free cash flow yield: 7.71%
Achieve EPS between $14.25 and $15.25 in 2026 and grow to $16.63 in 2027Diluted EPS: $0.66 per share
Manage mid-single digit revenue decline in 2026Revenue growth: 3.42%

Next proof point

Oct 28, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

1.3%Typical daily move · historical

Downside history

-14.3%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Biogen outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 10, 2026

What kind of bet this is

This investment represents a durable compounder with a focus on sustainable revenue growth and pipeline advancement. The current thesis state is stable, supported by recent earnings beats and a successful acquisition integration.

What's priced into Biogen

The market appears to have a neutral valuation stance on BIIB, with expectations slightly below peers. There is a low fragility tier, indicating that the current pricing reflects justified fundamentals without significant risk of sharp declines.

What the fundamentals likely do

Fundamentals are likely to show continued strength due to management's focus on revenue growth and pipeline advancements. The recent financial performance has been strong, but there is moderate risk from potential guidance cuts or economic downturns.

What Biogen hinges on

The thesis hinges on the ability of management to maintain guidance and deliver on pipeline advancements. Additionally, performance of sector bellwethers will be crucial in shaping market sentiment around BIIB.

Bottom line

Over the next 1 to 3 years, BIIB's performance will depend on management execution and sector dynamics. Not investment advice.

Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$16.50

$16.46 → $16.50 · observed estimates

FY2027 revenue$10.67B

$10.33B → $10.67B · observed estimates

Exact estimates & source dates

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$16.46	$10,329,510,180	29 / 28
2026-07-25	$16.39	$10,317,219,830	28 / 27
2026-07-26	$16.39	$10,317,219,830	28 / 27
2026-07-27	$16.42	$10,318,175,650	28 / 27
2026-07-28	$16.42	$10,318,175,650	28 / 27
2026-07-29	$16.48	$10,321,904,360	29 / 28
2026-07-30	$16.48	$10,321,904,360	29 / 28
2026-07-31	$16.54	$10,545,444,630	19 / 25
2026-08-01	$16.48	$10,321,904,360	29 / 28
2026-08-02	$16.57	$10,620,066,450	31 / 30
2026-08-03	$16.57	$10,620,066,450	31 / 30
2026-08-04	$16.57	$10,620,066,450	31 / 30
2026-08-05	$16.59	$10,624,903,010	32 / 31
2026-08-06	$16.59	$10,624,903,010	32 / 31
2026-08-07	$16.59	$10,628,614,883	21 / 26
2026-08-08	$16.59	$10,624,910,590	32 / 31
2026-08-09	$16.59	$10,624,910,590	32 / 31
2026-08-10	$16.59	$10,624,910,590	32 / 31
2026-08-11	$16.59	$10,628,614,883	21 / 26
2026-08-12	$16.60	$10,635,425,480	32 / 31
2026-08-13	$16.60	$10,635,425,480	32 / 31
2026-08-14	$16.59	$10,628,614,883	21 / 26
2026-08-15	$16.59	$10,628,614,883	21 / 26
2026-08-16	$16.59	$10,628,614,883	21 / 26
2026-08-17	$16.59	$10,628,614,883	21 / 26
2026-08-18	$16.59	$10,628,614,883	21 / 26
2026-08-19	$16.59	$10,628,614,883	20 / 26
2026-08-20	$16.54	$10,661,768,964	20 / 26
2026-08-21	$16.54	$10,661,768,964	20 / 26
2026-08-22	$16.54	$10,661,768,964	20 / 26
2026-08-23	$16.54	$10,661,768,964	20 / 26
2026-08-24	$16.54	$10,661,768,964	20 / 26
2026-08-25	$16.54	$10,661,768,964	20 / 26
2026-08-26	$16.54	$10,661,768,964	19 / 26
2026-08-27	$16.54	$10,661,768,964	19 / 26
2026-08-28	$16.54	$10,661,768,964	19 / 26
2026-08-29	$16.54	$10,661,768,964	19 / 26
2026-08-30	$16.54	$10,661,768,964	19 / 26
2026-08-31	$16.54	$10,661,768,964	19 / 26
2026-09-01	$16.54	$10,661,768,964	19 / 26
2026-09-02	$16.54	$10,661,768,964	19 / 26
2026-09-03	$16.55	$10,668,863,299	19 / 26
2026-09-04	$16.55	$10,668,863,299	19 / 26
2026-09-05	$16.55	$10,668,863,299	19 / 26
2026-09-06	$16.55	$10,668,863,299	19 / 26
2026-09-07	$16.55	$10,668,863,299	19 / 26
2026-09-08	$16.55	$10,668,863,299	19 / 26
2026-09-09	$16.55	$10,668,863,299	19 / 26
2026-09-10	$16.55	$10,668,863,299	19 / 26
2026-09-11	$16.55	$10,668,937,955	19 / 26
2026-09-12	$16.55	$10,668,937,955	19 / 26
2026-09-13	$16.55	$10,668,937,955	19 / 26
2026-09-14	$16.55	$10,668,937,955	19 / 26
2026-09-15	$16.55	$10,668,937,955	19 / 26
2026-09-16	$16.55	$10,668,937,955	19 / 26
2026-09-17	$16.55	$10,668,937,955	19 / 26
2026-09-18	$16.55	$10,668,937,955	19 / 26
2026-09-19	$16.55	$10,668,937,955	19 / 26
2026-09-20	$16.55	$10,668,937,955	20 / 27
2026-09-21	$16.55	$10,668,937,955	20 / 27
2026-09-22	$16.55	$10,668,937,955	20 / 27
2026-09-23	$16.55	$10,668,937,955	20 / 27
2026-09-24	$16.55	$10,668,937,955	20 / 27
2026-09-25	$16.55	$10,668,937,955	20 / 27
2026-09-26	$16.55	$10,668,937,955	20 / 27
2026-09-27	$16.55	$10,668,937,955	20 / 27
2026-09-28	$16.55	$10,668,937,955	20 / 27
2026-09-29	$16.55	$10,668,937,955	20 / 27
2026-09-30	$16.55	$10,668,937,955	20 / 27
2026-10-01	$16.55	$10,668,937,955	20 / 27
2026-10-02	$16.55	$10,668,937,955	20 / 27
2026-10-03	$16.55	$10,668,937,955	20 / 27
2026-10-04	$16.55	$10,668,937,955	20 / 27
2026-10-05	$16.55	$10,668,937,955	20 / 27
2026-10-06	$16.55	$10,668,931,504	20 / 27
2026-10-07	$16.55	$10,669,608,923	20 / 27
2026-10-08	$16.55	$10,669,608,923	20 / 27
2026-10-09	$16.53	$10,666,937,955	20 / 27
2026-10-10	$16.53	$10,666,937,955	20 / 27
2026-10-11	$16.55	$10,674,393,750	20 / 27
2026-10-12	$16.55	$10,674,393,750	20 / 27
2026-10-13	$16.57	$10,674,942,137	20 / 27
2026-10-14	$16.50	$10,674,432,607	20 / 27
2026-10-15	$16.50	$10,674,432,607	20 / 27

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings